Earnings Call Intelligence Subscribe
Home › Call Sheets › ZTS › Q1'26
Call sheet · Q1'26

Zoetis (ZTS)

Q1'26 earnings call · held May 7, 2026 · compared with the Q4'25 call · management-credibility review
6/12
Disclosure score
3 high, 5 medium, 2 low flags
Financial quality
Bottom line
The sleeper story everyone will miss: underlying organic growth was actually -5% globally once you strip out the $100M fiscal year accounting shift, and U.S. distributors destocked because end demand was weaker than Zoetis's sales into the channel. The obvious headline is competitive pressure in dermatology and parasiticides, but the real binding constraint is that competition is no longer expanding markets - it's pure share theft without the historical tailwind of category growth. Management admitted: 'Unlike prior competitive cycles, we do not currently have the benefit of underlying market expansion.' The most revealing quote came from CEO Peck acknowledging their vulnerability: 'As the market leader with significant share in premium products, we are at a point where our growth is less driven by new product cycles.' My view changes if they can prove Q2 distributor inventory restocking is real demand recovery rather than temporary channel dynamics, or if monthly Librela trends actually inflect positive rather than just 'stabilizing.'

The 30-second version

  • THE SLEEPER STORY: U.S. companion animal distributor destocking masked organic -5% decline despite flat reported growth
  • Premium pricing power evaporated: 'Price has played a larger role in the decision process' across key franchises
  • Guidance mathematically aggressive: Q1 flat performance somehow leads to 2-5% full-year growth

What changed this quarter

MetricQ4'25Q1'26Change
Global Revenue$2.4B (+4% YoY organic op)$2.3B (flat YoY organic op)400 bps deceleration to flat growth
Adjusted Net Income$648M (+4% YoY organic op)$646M (+1% YoY organic op)300 bps deceleration
U.S. Companion Animal$865M in Q4 implied$865M (-11% YoY)Sharp acceleration of decline
Key Dermatology Global$426M (+1% YoY Q4)$347M (-11% YoY)1200 bps deterioration
Simparica Franchise Global$333M (+3% YoY Q4)$385M (-1% YoY)400 bps deceleration to negative
OA Pain mAbs Global$137M (-11% YoY Q4)$140M (-8% YoY)300 bps improvement but still declining
International Revenue$1.1B (+7% YoY organic op Q4)$1.1B (+10% YoY organic op)300 bps acceleration
Livestock Global$756M (+9% YoY organic op Q4)$720M (+12% YoY organic op)300 bps acceleration
Adjusted Gross Margin71.9% full year 202571.8% (-10 bps YoY)Margin pressure emerging
Price Contribution3% Q4 implied2% of revenue growth100 bps weakening in pricing power

Accountability tracked

8 new promises made6 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full ZTS Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.